keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant sunitinib

keyword
https://www.readbyqxmd.com/read/29449091/adjuvant-therapies-in-nonmetastatic-renal-cell-carcinoma-a-review-of-the-literature
#1
REVIEW
Marco Bandini, Ariane Smith, Michele Marchioni, Raisa S Pompe, Tristan F Martel, Luca Cindolo, Francesco Montorsi, Shahrokh F Shariat, Alberto Briganti, Anil Kapoor, Umberto Capitanio, Pierre I Karakiewicz
To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer...
February 2, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29435133/elucidating-mechanisms-of-sunitinib-resistance-in-renal-cancer-an-integrated-pathological-molecular-analysis
#2
Henriett Butz, Qiang Ding, Roy Nofech-Mozes, Zsuzsanna Lichner, Heyu Ni, George M Yousef
Upon sunitinib treatment of metastatic renal cell carcinoma patients eventually acquire resistance. Our aim was to investigate microRNAs behind sunitinib resistance. We developed an in vivo xenograft and an in vitro model and compared morphological, immunhistochemical, transcriptomical and miRNome data changes during sunitinib response and resistance by performing next-generation mRNA and miRNA sequencing. Complex bioinformatics (pathway, BioFunction and network) analysis were performed. Results were validated by in vitro functional assays...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435010/chloroquine-potentiates-the-anticancer-effect-of-sunitinib-on-renal-cell-carcinoma-by-inhibiting-autophagy-and-inducing-apoptosis
#3
Man-Li Li, You-Zhi Xu, Wen-Jie Lu, Yong-Huai Li, Shi-Sheng Tan, Hong-Jun Lin, Tian-Ming Wu, Yan Li, Si-Ying Wang, Ying-Lan Zhao
Sunitinib based adjuvant chemotherapy combined with chloroquine (CQ) for the treatment of renal cell carcinoma (RCC) is in clinical trials; however, its anti-RCC effect and the mechanism remain unclear. In the present study, the anti-RCC effect of sunitinib with CQ and the underlying mechanism was investigated. An MTT assay demonstrated that CQ enhanced the proliferation inhibitory effect of sunitinib against the OS-RC-2 RCC cell line. CQ inhibited sunitinib-induced autophagy in OS-RC-2, which was evidenced by the inhibition of autophagic vacuoles, acidic vesicular organelle formation, light chain 3 (LC3)-II recruitment to the autophagosomes and the conversion of LC3-I to LC3-II, as induced by sunitinib...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433972/re-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy
#4
Amirali Salmasi, Izak Faiena, Alexandra Drakaki, Allan J Pantuck
No abstract text is available yet for this article.
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29409504/unusual-progression-of-renal-cell-carcinoma-with-carcinomatosis-peritoneii-and-krukenberg-tumour-and-alopecia-with-sunitinib-therapy-in-young-female
#5
Manoj Pandey, Mahendran Ramasamy, Mridula Shukla
BACKGROUND: Sunitinib is a multiple receptor tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma (RCC). It increases the median survival considerably with minimum side effects. Alopecia is one of the rare side effects. Metastasis to the ovary is also rare. We report a case of RCC metastasizing to the ovary developing alopecia early on starting sunitinib. CASE PRESENTATION: A 22-year-old hypothyroid girl underwent right radical nephrectomy for T2N0 RCC...
February 6, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29374054/immune-biomarkers-predictive-for-disease-free-survival-with-adjuvant-sunitinib-in-high-risk-locoregional-renal-cell-carcinoma-from-randomized-phase-iii%C3%A2-s-trac-study
#6
Daniel J George, Jean-Francois Martini, Michael Staehler, Robert J Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casy, Brigitte Laguerre, Hardev Pandha, Allan Pantuck, Anup Patel, Maria J Lechuga, Alain Ravaud
PURPOSE: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma in the S-TRAC trial (ClinicalTrials.gov number, NCT00375674). A prospectively-designed exploratory analysis of tissue biomarkers was conducted to identify predictors of treatment benefit. EXPERIMENTAL DESIGN: Tissue blocks were used for immunohistochemistry (IHC) staining of PD-L1, CD4, CD8, and CD68. DFS was compared between < versus ≥ median IHC parameter using the Kaplan-Meier method...
January 26, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29274030/fatigue-among-patients-with-renal-cell-carcinoma-receiving-adjuvant-sunitinib-or-sorafenib-patient-reported-outcomes-of-ecog-acrin-e2805-trial
#7
Fengmin Zhao, David Cella, Judith Manola, Robert S DiPaola, Lynne I Wagner, Naomi S B Haas
BACKGROUND: E2805 was a phase III trial to test whether adjuvant sunitinib or sorafenib could improve disease-free survival compared to placebo in patients with renal cell carcinoma. Patient-reported outcomes (PRO), focusing on fatigue, were evaluated as a secondary endpoint. PATIENTS AND METHODS: A total of 463 patients participated in the PRO study. Fatigue was measured by the FACIT Fatigue scale and PROMIS Fatigue SF1 measure at baseline, week 10, and week 22...
December 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29220298/gastrointestinal-stromal-tumors
#8
Margaret von Mehren, Heikki Joensuu
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29134564/seom-clinical-guideline-for-treatment-of-kidney-cancer-2017
#9
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma...
January 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29066509/tumor-microvessel-density-as-a-prognostic-marker-in-high-risk-renal-cell-carcinoma-patients-treated-on-ecog-acrin-e2805
#10
Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, Victoria Xin Wang, Christopher R Zito, Keith T Flaherty, Marta Boeke, Veronique M Neumeister, Robert L Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S DiPaola, Naomi Haas, Harriet M Kluger
PURPOSE: Increased vascularity is a hallmark of renal cell carcinoma (RCC). Microvessel density (MVD) is one measurement of tumor angiogenesis, however its utility as a biomarker of outcome is unknown. ECOG-ACRIN 2805 (E2805) enrolled 1,943 resected high-risk RCC patients randomized to adjuvant sunitinib, sorafenib, or placebo. We aimed to determine the prognostic and predictive role of MVD in RCC. METHODS: We obtained pre-treatment primary RCC nephrectomy tissues from 822 patients on E2805 and constructed tissue microarrays...
October 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29035731/postoperative-adjuvant-sorafenib-or-sunitinib-for-nonmetastatic-renal-cell-carcinoma-with-venous-tumor-thrombus-a-prospective-cohort-study
#11
Liangyou Gu, Hongzhao Li, Luyao Chen, Xintao Li, Baojun Wang, Qingbo Huang, Fan Zhang, Yang Fan, Yu Gao, Cheng Peng, Xin Ma, Xu Zhang
PURPOSE: To evaluate the efficacy and safety of antiangiogenic agents (sorafenib and sunitinib) as postoperative adjuvant therapy in patients with nonmetastatic renal cell carcinoma (RCC) and venous tumor thrombus (VTT). MATERIAL AND METHODS: From March 2006 to January 2016, 147 patients who met the inclusion criteria were enrolled; 27 patients received sorafenib, and 17 patients received sunitinib. After radical nephrectomy and thrombectomy, the duration of maintenance targeted medication treatment was approximately 1 year...
December 2017: Translational Oncology
https://www.readbyqxmd.com/read/29032154/are-we-ready-for-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma
#12
EDITORIAL
Jozefina Casuscelli, James J Hsieh
No abstract text is available yet for this article.
October 11, 2017: European Urology
https://www.readbyqxmd.com/read/28993730/molecular-guided-therapy-provides-sustained-clinical-response-in-refractory-choroid-plexus-carcinoma
#13
Albert Cornelius, Jessica Foley, Jeffrey Bond, Abhinav B Nagulapally, Julie Steinbrecher, William P D Hendricks, Maria Rich, Sangeeta Yendrembam, Genevieve Bergendahl, Jeffrey M Trent, Giselle S Sholler
Choroid plexus carcinomas (CPCs) are rare, aggressive pediatric brain tumors with no established curative therapy for relapsed disease, and poor survival rates. TP53 Mutation or dysfunction correlates with poor or no survival outcome in CPCs. Here, we report the case of a 4 month-old female who presented with disseminated CPC. After initial response to tumor resection and adjuvant-chemotherapy, the tumor recurred and metastasized with no response to aggressive relapse therapy suggesting genetic predisposition...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28967554/adjuvant-sunitinib-for-high-risk-renal-cell-carcinoma-after-nephrectomy-subgroup-analyses-and-updated-overall-survival-results
#14
Robert J Motzer, Alain Ravaud, Jean-Jacques Patard, Hardev S Pandha, Daniel J George, Anup Patel, Yen-Hwa Chang, Bernard Escudier, Frede Donskov, Ahmed Magheli, Giacomo Carteni, Brigitte Laguerre, Piotr Tomczak, Jan Breza, Paola Gerletti, Mariajose Lechuga, Xun Lin, Michelle Casey, Lucile Serfass, Allan J Pantuck, Michael Staehler
BACKGROUND: Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03). OBJECTIVE: To report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: Data for 615 patients randomized to sunitinib (n=309) or placebo (n=306) in the S-TRAC trial...
September 26, 2017: European Urology
https://www.readbyqxmd.com/read/28935400/adjuvant-sunitinib-in-high-risk-patients-with-uveal-melanoma-comparison-with-institutional-controls
#15
Matias E Valsecchi, Marlana Orloff, Rino Sato, Inna Chervoneva, Carol L Shields, Jerry A Shields, Michael J Mastrangelo, Takami Sato
PURPOSE: To compare overall survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with institutional controls. DESIGN: Retrospective cohort. PARTICIPANTS: Selection criteria were (1) monosomy 3 and 8q amplification by cytogenetic or DecisionDx-UM Class 2 and (2) monosomy 3 and large tumor size (T3-4 by American Joint Committee on Cancer classification). Exclusion criteria were date of diagnosis before 2007 or after 2013 and age <18 years...
September 18, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28932277/a-retrospective-review-of-the-multidisciplinary-management-of-medullary-thyroid-cancer-eligibility-for-systemic-therapy
#16
Georgia Geller, Janessa Laskin, Winson Y Cheung, Cheryl Ho
BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for 1-2% of all thyroid cancers. The clinical course of metastatic disease can be indolent. Our aim was to characterize the natural history of disease to evaluate the true proportion of patients who would be eligible for the currently available systemic therapies. METHODS: The British Columbia Cancer Agency (BCCA) provides cancer care to a population of 4.6 million. A retrospective chart review was conducted of all patients with MTC referred to the BCCA from 1991 to 2013...
2017: Thyroid Research
https://www.readbyqxmd.com/read/28879504/-tki%C3%A2-2-0-changes-in-the-medical-treatment-of-renal-cell-carcinoma
#17
REVIEW
V Stühler, S Kruck, M Hegemann, M Notohamiprodjo, T Todenhöfer, N Kröger, A Stenzl, J Bedke
Only for renal cell carcinoma (RCC) in a local stage curative treatment option by surgical resection exists. For metastatic disease the 5‑year survival rate decreases radically. A factor that contributes to this is the low sensibility to radiation and chemotherapeutics. Since the approval of the tyrosine kinase inhibitors in 2006 effective drugs for the treatment of mRCC is available. The specific inhibition of the vascular-endothelial-growth (VEGF)-receptor and the "mammalian Target of Rapamycin" (mTOR) leads to a prolongation of the progression-free survival as well as the overall survival rate...
September 6, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28728992/retroperitoneal-lymphadenectomy-in-high-risk-nonmetastatic-renal-cell-carcinoma-an-analysis-of-the-assure-ecog-acrin-2805-adjuvant-trial
#18
Benjamin T Ristau, Judi Manola, Naomi B Haas, Daniel Y C Heng, Edward M Messing, Christopher G Wood, Christopher J Kane, Robert S DiPaola, Robert G Uzzo
PURPOSE: Lymphadenectomy is a well established practice for many urological malignancies but its role in renal cell carcinoma is less clear. Our primary objective was to determine whether lymphadenectomy impacted survival in patients with fully resected, high risk renal cell carcinoma. MATERIALS AND METHODS: Patients with fully resected, high risk, nonmetastatic renal cell carcinoma were randomized to adjuvant sorafenib, sunitinib or placebo in the ASSURE (Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma) trial...
July 18, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28685083/complete-response-to-second-line-chemotherapy-with-sunitinib-of-a-gastrointestinal-stromal-tumor-a-case-report
#19
Tsuyoshi Shirakawa, Tomoya Hirata, Kosuke Maemura, Toshiyuki Goto, Yoshiya Shimao, Kosuke Marutsuka, Yuji Ueda, Ikuo Kikuchi
Gastrointestinal stromal tumors (GISTs) are a type of sarcoma, and the most common mesenchymal tumor of the gastrointestinal tract. Systemic chemotherapy is recommended for unresectable or metastatic GISTs. Imatinib is an oral multitargeted receptor tyrosine kinase inhibitor that is effective as adjuvant chemotherapy for primary high-risk cases, and as palliative chemotherapy for unresectable or metastatic cases. For imatinib-resistant cases, second-line chemotherapy with sunitinib is recommended due to significantly longer median progression-free survival and higher response rates compared with a placebo...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28680753/efficacy-of-vaccination-with-tumor-exosome-loaded-dendritic-cells-combined-with-cytotoxic-drug-treatment-in-pancreatic-cancer
#20
Li Xiao, Ulrike Erb, Kun Zhao, Thilo Hackert, Margot Zöller
Pancreatic cancer (PaCa) has a dismal prognosis and adjuvant immunotherapy frequently is of low efficacy due to immunosuppressive features of PaCa and PaCa-stroma. We here explored, whether the efficacy of vaccination with tumor-exosome (TEX)-loaded dendritic cells (DC) can be improved by combining with drugs affecting myeloid-derived suppressor cells (MDSC). Experiments were performed with the UNKC6141 PaCa line. UNKC6141 TEX-loaded DC were weekly intravenously injected, mice additionally receiving Gemcitabine (GEM) and/or ATRA and/or Sunitinib (Sun)...
2017: Oncoimmunology
keyword
keyword
110017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"